A Study to Assess the Effect of QAW039 in Non-atopic Asthmatic Patients

Summary

The purpose of the study was to assess the clinical effect of QAW039 in non-atopic asthmatics taking low dose Inhaled Corticosteroid (ICS) as background therapy.

Timeline

Start

2013-05

Primary completion

2016-02

Completion

2016-02

Outcome

Missed primary endpoint

registry QAW039 450 mg qd Non-atopic vs Placebo Non-atopic; p = 0.7269 NCT01836471 ↗

registry least squares mean 0.01 (90% CI -0.5 to 0.08) NCT01836471 ↗

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Fluticasone	Other / unclassified	100 ug	Inhaled
Comparator	Fluticasone	Other / unclassified	250 ug	Inhaled
Subject	fevipiprant	Small molecule	450 mg	Oral

Indications